Agoracom Blog Home

Posts Tagged ‘MMJ’

Tetra Bio-Pharma $TBP.ca getting ready to file a clinical trial application to initiate phase 3 clinical trial on terminal cancer patients in the coming weeks

Posted by AGORACOM-JC at 8:17 AM on Monday, September 18th, 2017

Tbp large new

  • Announced that it will be filing a clinical trial application in the coming weeks to therapeutic products directorate 
  • Purpose to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients
  • With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001

OTTAWA, ONTARIO–(Sept. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announces that it will be filing a clinical trial application (CTA) in the coming weeks to therapeutic products directorate (TPD) to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients. With this filing, Tetra expects to be on time with its previously announced schedule with the development of PPP001. The corporation worked with physicians of Sante Cannabis to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients. In addition, as part of the clinical trial, Tetra will collect the pharmacoeconomics evidence required from provincial insurers in order to support the reimbursement of the first cannabis prescription drug.

A significant percentage of patients placed on a cannabis treatment suffer from side effects that are not tolerable. This can lead to patients stopping a potentially effective therapy. As part of its early phase clinical research, Tetra developed dosing strategies to minimize moderate and severe side effects in patients. This dosing strategy was developed in healthy volunteers over the last few months and has shown to be effective in reducing the severity of the side effects and preventing certain serious ones. This allows TBP to initiate its Phase 3 trial based on clinical data proposing a more tolerable approach to consuming smoked cannabis and to assess PPP001 in terminal cancer patients. This is a significant step in the development of a safe, tolerable and effective new drug for the management of chronic pain in terminal cancer patients with co-morbidities.

This will be the first Phase 3 clinical trial studying the therapeutic benefits of a smoked dried cannabis prescription drug in terminal cancer patients. Due to the status of cannabis under the Controlled Drugs and Substances Act in Canada, over the last four months the corporation developed procedures and methods that would both satisfy the Narcotic Controls Regulations and ensure the protection of patients consuming the cannabis. The corporation is confident that these procedures will be well received by Health Canada as they ensure compliance with both the Food and Drug Act and Controlled Drugs and Substances Act.

Tetra also reports that it has restructured its investors and public relation functions to integrate them with the marketing and communication functions. Mr. Edward Miller is leaving the Corporation effective as of today. We want to thank Mr. Miller for the work he has done for the Corporation over the last months and wish him all the success he deserves for his new professional projects.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra has three core expertise: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based drugs.

More information at: www.tetrabiopharma.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Source: Tetra Bio-Pharma

Tetra Bio-Pharma Inc.
Anne-Sophie Courtois
Vice- President Marketing & Communication
(514) 360 8040 Ext. 210
[email protected]
www.tetrabiopharma.com

Namaste $N.ca Announces Supply Agreement With Israel-Based #Cannabis Producer Cannbit Ltd. #MMJ #Vapes

Posted by AGORACOM-JC at 8:32 AM on Friday, September 15th, 2017

Nlogo

  • Wholly owned subsidiary, Cannmart Inc, has signed a supply agreement with Israeli-based producer Cannbit
  • Will supply medical cannabis products sourced from Cannbit in Israel,
  • To be sold exclusively in Canada through CannMart and Namaste sales channels
  • Represents a fundamental step in Namaste’s growth strategy to develop a marketplace

VANCOUVER, British Columbia, Sept. 15, 2017 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ)(OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“CannMart”), has signed a supply agreement (the “Agreement”) with Israeli-based producer Cannbit Ltd. (“Cannbit”).

The Agreement, subject to approval by Health Canada, will supply medical cannabis products sourced from Cannbit in Israel, to be sold exclusively in Canada through CannMart and Namaste sales channels. This Agreement represents a fundamental step in Namaste’s growth strategy to develop a marketplace for Canadian medical cannabis that will include product sourced both domestically and internationally.

Namaste will further pursue supply agreements with domestic and international producers in developing a unique online platform to provide a larger variety of medical cannabis products to patients sourced from domestic and international producers. Namaste recognizes that Israel is providing the medical cannabis industry with leading research and intends to provide Israeli-grown products to Canadian medical cannabis patients.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to sign this Agreement. We had the opportunity of meeting with the Cannbit management team and feel very strongly that Namaste will bring some of the highest quality medical cannabis available in the world to our Canadian patients. Through our new platform, Namaste MD, we will be offering a full-service platform for users to flow through an initial consultation to issuance of a prescription. They will then be provided with access to our marketplace of medical cannabis products that will be sourced from multiple producers in Canada, as well as countries like Israel, that are innovators in research and development in our industry.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Invested in #MMJ stocks like Cannagrow $CGRW ? Tetra Bio-Pharma $TBP.ca will benefit from IP created at University of New Brunswick

Posted by AGORACOM-JC at 12:36 PM on Thursday, September 14th, 2017

Tbp large new

TBP: TSX-V

WHY TETRA BIO-PHARMA?

  • Only pharmaceutical company to have clinical studies for smoked marijuana;
  • Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
  • Company is financially sound, with enough cash to pay for the $1.2 million Phase III clinical trials of PPP001.
  • Preparations for the Phase III trial of PPP001 are to start in Q4 2017 with approximately 600 subjects;
  • Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
  • Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected
  • Putting in place the necessary manufacturing capabilities to address this increasing demand and to ensure the highest standards of quality control.

Marijuana Company of America $MCOA Announces the Release of #hempSMART Full Spectrum CBD Drops #MMJ

Posted by AGORACOM-JC at 7:49 AM on Wednesday, September 13th, 2017

15233 mcoa

  • Released its new Full Spectrum Drops, available in 250mg bottles, enriched with non-psychoactive industrial hemp derived CBD
  • Full Spectrum Drops are now available for purchase by Company affiliates and customers at the Company’s newly redesigned website and sales platform for affiliates at www.hempsmart.com.

ESCONDIDO, CA–(Sep 13, 2017) –  MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC PINK: MCOA), an innovative cannabis research and development and industrial hemp corporation, is pleased to announce that its wholly owned subsidiary, hempSMARTâ„¢, Inc., today released its new Full Spectrum Drops, available in 250mg bottles, enriched with non-psychoactive industrial hemp derived CBD.

After several months of market research, competitive comparison and product formulation, the proprietary hempSMARTâ„¢ Full Spectrum Drops are now available for purchase by Company affiliates and customers at the Company’s newly redesigned website and sales platform for affiliates at www.hempsmart.com.

The hempSMARTâ„¢ Full Spectrum Drops are available in four different flavors: lemon, mint, orange and strawberry, and are formulated with phytocannabinoid rich full spectrum hemp CBD oil that is free of the THC isolate, and provides the desired “Entourage Effect” of naturally occurring CBD, Terpenes, and complimentary Cannabinoids.

Commenting on the product release, Tim Alvater, the Company’s head of marketing, stated, “The opportunity to develop products using the finest ingredients, coupled with quality non-psychoactive CBD and a marketing plan developed by top affiliate marketing people with decades of experience, gives us the green light to aggressively open the channels of distribution in the US as well as on a global scale. We are proud to be at the forefront of the industrial hemp derived CBD revolution.”

Paul Vetter, a member of hempSMART’s Product Development Advisory Board, commented: “hempSMART’s proprietary Full Spectrum industrially derived CBD free of the THC isolate, with its full array of naturally occurring terpenes, takes CBD supplementation to a new level.”

Donald Steinberg, CEO of MCOA, who previously created multiple affiliate based marketing companies, observed: “The public awareness and acceptance of CBD based products is expanding on a global basis, and at hempSMARTâ„¢ we are prepared to meet this global demand. Along with our team of executives, we have the products in place, the software, the marketing and the affiliate compensation plan to implement our program of market distribution to an affiliate based marketing group promoting our products in the United States.”

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMARTâ„¢”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Marijuana Company of America $MCOA.us Announces #hempSMART 2.0 With New Website and Affiliate Program

Posted by AGORACOM-JC at 8:54 AM on Thursday, September 7th, 2017

15233 mcoa

  • Announced a major update of hempSMARTâ„¢, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division
  • www.hempSmart.com and its network marketing platform have been completely redeveloped
  • Provides a more user friendly experience to its affiliates and customers

ESCONDIDO, CA–(Sep 7, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company“) (OTC PINK: MCOA), an innovative cannabis and hemp marketing and distribution company, is pleased to announce a major update of hempSMARTâ„¢, the Company’s wellness focused Cannabidiol (CBD) marketing and distribution division.

The hempSMART website: www.hempSmart.com and its network marketing platform have been completely redeveloped to provide a more user friendly experience to its affiliates and customers, and to also provide users with the comprehensive tools necessary to succeed in the growing $1.9 Trillion Wellness Industry.

The new website and network marketing platform have a significantly improved design, expanded content and a more user friendly e-commerce platform that offers the ability to easily expand due to the flexibility of the business platform it is built on. Affiliate’s will now experience a more effective, reliable and streamlined sales process to rapidly expand the Company’s consumer base and Affiliate success stories.

The new hempSMART Affiliate sales and distribution method is designed to ensure that our Affiliates play a leading role in the rapidly emerging Cannabidiol (CBD) movement within the Wellness Industry. The Company is in ongoing discussions about expanding internationally into multiple countries in 2018.

“The solid foundation that our new system and online platform offers will enable our Affiliates to fully utilize their abilities to grow their organizations in the U.S. and globally. Our team is in place, our products are being well received in the market, and we are in an industry that is experiencing exponential growth. We are building a strong foundation of technology, products and a strategic marketing plan that is designed to offer great benefits to our Affiliates who are the key to our success. We look forward to a robust and exciting time for our company,” said CEO, Donald Steinberg.

About Marijuana Company of America, Inc.

MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products containing CBD under the brand name “hempSMARTâ„¢”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

FORWARD LOOKING STATEMENT
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:
MarijuanaCompanyofAmerica.com
hempSMART.com
agoracom.com/ir/MarijuanaCompanyofAmerica

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Tetra Bio-Pharma $TBP.ca Receives Approval to List on the #TSX-V #MMJ

Posted by AGORACOM-JC at 8:09 AM on Wednesday, August 16th, 2017

Tbp large new

  • Approved for trading on the TSX Venture Exchange Under TBP:TSX-V

OTTAWA, ONTARIO–(Aug. 16, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that its common shares have been approved for trading on the TSX Venture Exchange and that it has applied for voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). Tetra’s shares will commence trading on the TSX Venture on the opening of markets on Wednesday, August 16, 2017, under the symbol “TBP”.

“We are pleased to announce that the TSX Venture Exchange has accepted our application for listing,” said Bernard Fortier, CEO of Tetra Bio-Pharma Inc. “We believe this move will enhance trading liquidity and continue to increase market adoption of our business model, thereby enhancing shareholder value. We look forward to aggressively executing our business plan as we build the leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”

Mr. Fortier further added, “We would like to thank the CSE for all their support and commitment to Tetra these past years in our evolution as an organization.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma is a multi subsidiary publicly traded company (TSX VENTURE:TBP) (OTCQB: TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
[email protected]

INTERVIEW: Tetra Bio-Pharma Developing Pharma Derived From Cannabis and Other Medicinal Plants $TBP.ca

Posted by AGORACOM-JC at 11:41 AM on Tuesday, November 8th, 2016

Pharmaceutical Division – PhytoPain Pharma

  • Developing and commercialization of botanical based pharmaceuticals
  • Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Recent Highlights

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
  • Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

Hub On AGORACOM / Corporate Profile / Watch Interview

Medical Marijuana Seems To Reduce Deaths From Pharmaceuticals $MCOA.us $GCI.ca

Posted by AGORACOM-JC at 4:47 PM on Thursday, September 22nd, 2016
  • Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana
  • That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

BY: Jacob Sullum , Contributor

I cover the war on drugs from a conscientious objector’s perspective.

Opinions expressed by Forbes Contributors are their own.

Marijuana jars at the West Coast Collective, a dispensary in Los Angeles (Image: Frederic J. Brown/AFP/Getty Images)

Insys Therapeutics, the Arizona-based pharmaceutical company that recently became the biggest financial supporter of the campaign against marijuana legalization in that state, makes an oral spray that delivers the opioid painkiller fentanyl and plans to market another one that contains dronabinol, a synthetic version of THC. Insys says it gave $500,000 to the main group opposing Arizona’s legalization initiative because the measure “fails to protect the safety of Arizona’s citizens, and particularly its children.” But one needn’t be terribly cynical to surmise that Insys also worries about the impact that legalization might have on its bottom line, since marijuana could compete with its products.

A new study suggests Insys has good reason to worry. In an article published last week by the American Journal of Public Health, Columbia University epidemiologist June Kim and her colleagues report that fatally injured drivers are less likely to test positive for opioids in states that allow medical use of marijuana. That finding, together with the results of earlier studies, indicates that making marijuana legally available to patients saves lives by reducing their consumption of more dangerous medications.

Kim et al. collected data from the Fatality Analysis Reporting System (FARS) for 1999 through 2013, focusing on 18 states that drug-tested at least 80% of drivers who died in crashes. They found that drivers between the ages of 21 and 40 were half as likely to test positive for opioids in states that had implemented medical marijuana laws (MMLs) as in states that had not.

“Among 21-to-40-year-old deceased drivers, crashing in states with an operational MML was associated with lower odds of testing positive for opioids than crashing in MML states before these laws were operational,” the researchers write. “Although we found a significant association only among drivers aged 21 to 40 years, the age specificity of this finding coheres with what we know about MMLs: a minimum age requirement restricts access to medical marijuana for most patients younger than 21 years, and most surveyed medical marijuana patients are younger than 45 years.”

The fact that a driver tested positive for opioids does not necessarily mean the painkillers he took contributed to the crash, so it is not safe to draw any conclusions about medical marijuana’s impact on traffic safety from this study. But the FARS data are an indirect way of measuring the extent of opioid consumption in a given state. Kim et al. note that “severe or chronic pain is among the most common indications cited by medical marijuana patients.” It therefore makes sense that opioid use would decline (or rise less) in states that recognize cannabis as a medicine.

Source: http://www.forbes.com/sites/jacobsullum/2016/09/22/medical-marijuana-seems-to-reduce-deaths-from-pharmaceuticals/#1a6c82b7396e

PhytoPain Pharma Announces Interview With Radio-Canada Regarding Its Development of a Prescription Marijuana Drug $GCI.ca

Posted by AGORACOM-JC at 9:28 AM on Thursday, September 22nd, 2016

Growpros_hub_large

OTTAWA, ONTARIO–(Sept. 22, 2016) – PhytoPain Pharma (“PPP”), a subsidiary of GrowPros Cannabis Ventures Inc. (“GrowPros” or the “Company” or “GCI“) (CSE:GCI), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it gave an interview to the journalist Brigitte Bureau of Radio-Canada regarding the development of a prescription marijuana drug. Shareholders can view the interview on CBC’s website at http://ici.radio-canada.ca/regions/ottawa/2016/09/21/008-marijuana-medicinale-legalisation-gouvernement-trudeau.shtml

According to Dr. G. Chamberland, Chief Scientific Officer, “PPP is developing a prescription drug marijuana product for consumption via inhalation “smoking”. As part of its mission of bringing botanical-based therapies to patients with chronic diseases while maintaining the characteristics and properties of natural health products but backed by the scientific research and development of Pharma industry. Over the next years, the corporation is planning to develop the evidence to support the prescription of marijuana by physicians and to seek coverage by provincial and federal insurers.” “By implementing this approach, we believe that PPP is addressing the missing link that has existed for years as the major barrier of access to medical cannabis by both patients and physicians across the globe“, commented Ryan Brown, Vice-President of Business Development and Director of Communications for GCI.

Dr. Chamberland further commented that the company intends on submitting a Clinical Trial Application later this year (pre-CTA submitted in August 2016 as per previous news release) and when authorized by Health Canada would initiate its Phase I trial in humans later this year. “PPP001 is in its early stages of development, but based on published clinical trial data, the company is confident that it can bring this product to the market after completing the studies required by regulatory agencies“, commented Dr. Chamberland.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Dr. Guy Chamberland
Chief Scientific Officer
(514) 220-9225

GrowPros Cannabis Ventures Inc.
Andre Audet
Executive Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Ryan Brown
President, GrowPros MMP Inc.
(613) 421-8402

GrowPros Changes Its Name to Tetra Bio-Pharma Inc. and Announces the Results of Its Annual Shareholders Meeting $GCI.ca

Posted by AGORACOM-JC at 4:39 PM on Monday, September 19th, 2016

Growpros_hub_large

  • Selected Tetra Bio-Pharma Inc. as the new name for the Company
  • Company also announces the re-appointment of Mr. André Audet as Director of GrowPros and welcomes three new directors on its Board, Mr. André Rancourt, Mr. Robert Brouillette, and Mr. Benoit Chotard.

OTTAWA, ONTARIO–(Sept. 19, 2016) – GrowPros Cannabis Ventures Inc. (“GrowPros” or “the Company”) (CSE:GCI) is pleased to announce that its shareholders have approved an amendment to the Company’s articles of incorporation in order to change its name. The Board of Directors, at a special meeting following the annual shareholders meeting, has selected Tetra Bio-Pharma Inc. as the new name for the Company.

The Company also announces the re-appointment of Mr. André Audet as Director of GrowPros and welcomes three new directors on its Board, Mr. André Rancourt, Mr. Robert Brouillette, and Mr. Benoit Chotard. (Reference to News Release of August 25, 2016)

The firm of McGovern Hurley Cunningham, LLP, was re-appointed as auditors of the Company.

Shareholders have approved the Board’s request for consolidation of the share capital of the Company on the basis of a consolidation ratio of one (1) post-consolidation share for every three (3) pre-consolidation shares. As previously released the consolidation will only be implemented in the case of a major business development.

Non-Brokered Private Placement

The Company also announces a non-brokered private placement (the “Offering”) comprised of 5,000,000 units at a price of $0.05 per unit for gross proceeds of $250,000. Each unit will consist of one common share and one transferable warrant. Each warrant entitles the holder to purchase one common share at a price of $0.07 for a period of twenty-four months following the closing of the Offering. All securities issued pursuant to the private placement are subject to a four-month hold period from the closing date and are subject to all necessary regulatory approvals.

In connection with the private placement, the Company may pay finder’s fees.

The proceeds of the private placement will be used to fund general working capital.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

GrowPros Cannabis Ventures Inc.
Andre Rancourt
Interim Chief Executive Officer
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Andre Audet
Chairman
(613) 421-8402

GrowPros Cannabis Ventures Inc.
Ryan Brown
Grow Pros MMP Inc. President
(613) 421-8402